Blood tests distinguish active TB but miss early changes in close contacts

Tuberculosis control depends not only on treating people with active disease but also on identifying which close contacts of tuberculosis index cases are truly infected or at risk of developing illness. In a study led by Sudhasini Panda, researchers set out to see whether detailed immune profiling of blood could reveal differences among close contacts defined by QuantiFERON (QFT) test results. The team compared contacts who were QFT-positive (QFT+), QFT-negative (QFT-), and those whose QFT results were changing over time, often called QFT converters or individuals with increasing QFT responses. They also compared these contact groups with patients who had active TB (ATB) at diagnosis and then followed some ATB patients through treatment. Using standard ex vivo immune profiling approaches, the researchers measured several immune cell types and antigen-specific responses to explore whether these blood measures could capture subtle immunological transitions that might indicate early or subclinical infection among contacts. The goal was to determine whether blood-based immunology could go beyond the binary QFT readout and provide actionable insights about infection status among people exposed to an index TB case.

The investigators used antigen-specific assays, including the activation-induced marker (AIM) assay, alongside broader ex vivo immune cell phenotyping to compare groups. The AIM assay detected higher antigen-specific CD4 T cell responses in QFT+ individuals compared to QFT- individuals, indicating that some antigen-specific signals align with the QFT classification. However, other blood-based profiling measures failed to distinguish between QFT subgroups, and overall the ex vivo immune profiling did not capture subtle immunological transitions among QFT converters or individuals with increasing QFT responses. In contrast, individuals with active TB (ATB) showed clear immune perturbations: at diagnosis, ATB patients exhibited significantly elevated frequencies of antigen-specific CD4 T cells, increased activated T cells, and higher frequencies of intermediate monocytes and NK cells compared to QFT+/QFT- contacts. Many of these immune features declined with treatment, consistent with therapy-associated immune resolution. The study also observed shifts in T helper subsets and effector memory populations over the course of treatment, documenting dynamic immune changes linked to active disease and its treatment.

Taken together, these results suggest a mixed outlook for blood-based immune profiling in TB contact management. On the positive side, ex vivo immune profiling can robustly distinguish active TB from non-diseased states, capturing the immune perturbations that characterize ATB and their resolution with therapy. On the other hand, the same approaches lack the resolution needed to separate QFT-defined subgroups among close contacts based on QFT dynamics alone. This could mean two things: either close contacts are immunologically similar regardless of QFT status, or blood-based phenotyping simply cannot detect the early or subclinical immune shifts that precede overt infection. The study highlights the challenge of using conventional ex vivo blood profiling to find early markers of progression among contacts and underscores the need for caution when interpreting blood immune readouts for contact screening and risk stratification.